TME PHARMA Aktie

 

TME Pharma extends loan to 2027, adds 30% warrants, cash runway Q2 2027, aims to boost NOX‑A12/E36 development. Funding €2.06M, early bond redemption €163k...

TME Pharma provides update on its activities...

TME management is extending the maturity of the debt to enlarge financial visibility into Q2 of 2027 and prevent further dilution....

TME signs LOI for interesting and potentially profitable collaboration with a German company active in precious metals...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025. TME Pharma additionally announces that it has received notification that Diede Van Den Ouden, Chief Executive Officer and a Person Discharging Managerial Responsibilities ("PDMR"), has purchased an additional 300,000 ordinary shares in the Company at an average price per share of €0.0927. The shares were acquired through an on-market transaction on Euronext Growth Paris on Friday 19 September 2025. Following this transaction, Mr Van Ouden holds a total of 2,300,000 ordinary shares. Statement from the CEO “My share purchases are an indication of my strong belief in ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Aram Mangasarian. The shareholders representing 16.67% of the total issued and outstanding share capital on May 28, 2025, were represented at the AGM which took place on June 25, 2025, at 03:00 p.m. CEST. “On behalf of the Board and the entire TME Pharma team I would like to welcome Diede van den Ouden as our new CEO. Diede's commitment to TME Pharma, demonstrated both as a significant shareholder and an active supporter, gives us great confidence as we enter this next chapter,” said Maurizio PetitBon, Chairma...

Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025 Operational costs to be strongly reduced through outsourced staffing model as from July 1, 2025 while maintaining the ability to advance both NOX-A12 and NOX-E36 assets Streamlined Supervisory Board with two members stepping down at upcoming AGM Management confident in securing non-dilutive financing to cover short-term operational needs Support for the new strategy and CEO nomination from existing shareholders with significant shareholdings BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners. The strat...

Total €7.6 million raised through multiple transactions All convertible debt instruments removed from balance sheet during 2024 Commitment to lean cost structure while focusing on completing strategic goals Next clinical development steps for NOX-A12 validated by regulators Pursuit of several transaction structures in parallel for the company's drug candidates BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update. The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma's website (www.tmepharma.com). “TME Pharma achieved a number of significant clinical and regulatory milestones in 2024 and, as 2025 progresses, we remain committed to advanci...